The US Food and Drug Administration recently updated its guidelines for dispensing mifepristone (the “abortion pill”) to now include certified pharmacies.
Mifepristone (Mifeprex), in a regimen with misoprostol, have been approved by the US Food and Drug Administration (FDA) to be dispensed to pharmacies for consumer use.
Mifepristone, also known as RU-486, is a medication used to terminate a pregnancy. The combination is 97% effective during the first 63 days of pregnancy. Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, and cause an abortion.
Both Mifeprex and the generic mifepristone tablets (200 mg), are available under the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program, which produces the requirements that must be adhered to for medical termination of a pregnancy through 10 weeks. Under this program, mifepristone may be dispensed in person or by mail.
The FDA originally approved Mifeprex in 2000 and in 2019 approved the generic version, at which time the agency also approved a single shared REMS system for all mifepristone products. Until recently, the drug could only be dispensed by a few mail-order pharmacies or certified doctors and clinics. Under the current program:
--Mifepristone must be prescribed by a health care provider and is certified in the Mifepristone REMS Program.
--A patient agreement form must be reviewed with and signed by the patient and the health care provider with the risks of the mifepristone treatment being fully explained to the patient.
--The patient must be provided with a copy of the Patient Agreement Form and mifepristone Medication Guide.
--Mifepristone can only be dispensed under the supervision of a certified prescriber or by a certified pharmacy.
The FDA did not issue an announcement but instead updated its website to reflect the decision, as well as adding a series of questions and answers. The 2 manufacturers of the pill, Danco Laboratories and GenBioPro released statements saying the agency had informed them of their action.
Reference
Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation. US Food and Drug Administration. January 3, 2023. Accessed January 5, 2023. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-about-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Treating heavy menstrual bleeding: Levonorgestrel system vs combined oral contraceptives
November 8th 2023In a recent study, patients who were treated for heavy menstrual bleeding with the levonorgestrel intrauterine system had similar changes in bleeding-related quality of life as those using combined oral contraceptives for treatment.
Read More
Enhancing contraceptive use among female smokers
October 26th 2023Women of reproductive age often use combined hormonal contraceptives, which are available orally, as a vaginal ring, or as a transdermal patch. However, CHCs are associated with increased risks of venous thromboembolism and myocardial infarction (MI).
Read More